Extended-release pramipexole in early Parkinson disease A 33-week randomized controlled trial

Neurology

Volumn 77, Issue 8, 2011, Pages 759-766

  Poewe, W ^a   Rascol, O ^b   Barone, P ^c   Hauser, R A ^d   Mizuno, Y ^e   Haaksma, M ^f   Salin, L ^g   Juhel, N ^g   Schapira, A H V ^h,i  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CNRS   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^h BOEHRINGER INGELHEIM   (France)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDED RELEASE PRAMIPEXOLE; LEVODOPA; PLACEBO; PRAMIPEXOLE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOL;

ADULT; ARTICLE; BRADYKINESIA; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; INATTENTION TREMOR; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SOMNOLENCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; XEROSTOMIA; AGED; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; QUESTIONNAIRE; TIME; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053014870     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822affb0     Document Type: Article

References (19)

1. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17. (Pubitemid 34041931)
2. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society- European Section: part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13:1170-1185. (Pubitemid 44581464)
3. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. Available at: guidance.nice.org.uk/CG35. Accessed May 20, 2010.
4. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995. (Pubitemid 44044780)
5. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society- European Section (MDS-ES): part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-1202. (Pubitemid 44581465)
6. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidencebased medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
7. Koenen-Bergmann M, Haertter S, Schepers C. A multiple rising-dose bioequivalence phase I study with a pramipexole extended release (ER) formulation. Eur J Neurol 2008;15(suppl 3):97.
8. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. National Institute of Mental Health. Early clinical drug evaluation unit (ECDEU): clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised ed. Rockville, MD: National Institute of Mental Health; 1976:216-222.
11. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan; 1987:153-163.
12. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-357. (Pubitemid 27448379)
13. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-741. (Pubitemid 28121072)
14. Hauser RA, Schapira AHV, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010;25:2542-2549.
15. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
16. Grant JE, Levine L, Kim D, Potenza MN. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005;162:2184-2188. (Pubitemid 41598279)
17. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. Mov Disord 2006;21:1200-1207. (Pubitemid 44336608)
18. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the Unified Parkinson's Disease Rating Scale. Arch Neurol 2010;67:64-70.
19. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-832.